UroVaxom

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| type = vaccine

| image =

| alt =

| caption =

| target = Escherichia coli

| vaccine_type = killed

| pronounce =

| tradename = UroVaxom

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Oral (tablet){{cite journal | vauthors = Hughes T, Juliebø-Jones P, Saada L, Saeed K, Somani BK | title = Recurrent urinary tract infections in adults: a practical guide | journal = British Journal of Hospital Medicine | volume = 82 | issue = 12 | pages = 1–11 | date = December 2021 | pmid = 34983214 | doi = 10.12968/hmed.2021.0337 }}

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| PubChem =

| DrugBank =

| synonyms = OM-89; OM-8980

}}

UroVaxom (developmental code names OM-89, OM-8980) is a vaccine against urinary tract infections (UTIs).{{cite web | title=OM 8980 | website=AdisInsight | date=16 August 2022 | url=https://adisinsight.springer.com/drugs/800000983 | access-date=26 February 2025}}{{cite journal | vauthors = O'Brien VP, Hannan TJ, Nielsen HV, Hultgren SJ | title = Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections | journal = Microbiology Spectrum | volume = 4 | issue = 1 | date = February 2016 | pmid = 26999391 | pmc = 4887100 | doi = 10.1128/microbiolspec.UTI-0013-2012 }}{{cite journal | vauthors = Prattley S, Geraghty R, Moore M, Somani BK | title = Role of Vaccines for Recurrent Urinary Tract Infections: A Systematic Review | journal = European Urology Focus | volume = 6 | issue = 3 | pages = 593–604 | date = May 2020 | pmid = 31806578 | doi = 10.1016/j.euf.2019.11.002 }} It is an extract of 18{{nbsp}}strains of killed Escherichia coli administered as an oral tablet once daily for 3{{nbsp}}months. The vaccine is marketed for use in the prevention of recurrent UTIs in some European countries. It was also being studied for treatment of prostatitis but was discontinued. UroVaxom was initially developed in the 1980s.{{cite journal | vauthors = Huttner A, Gambillara V | title = The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli | journal = Clinical Microbiology and Infection | volume = 24 | issue = 10 | pages = 1046–1050 | date = October 2018 | pmid = 29803843 | doi = 10.1016/j.cmi.2018.05.009 }}